



NEW ENGLAND

CEPAC


COMPARATIVE EFFECTIVENESS
PUBLIC ADVISORY COUNCIL

Semaglutide and Tirzepatide for Obesity: Public Meeting

Thursday • November 13th, 2025 • 10:00 AM ET

Virtual Meeting Agenda

Connect with ICER on our social media channels



<p>10:00 AM – 10:20 AM ET</p>	<p>Meeting Convened and Opening Remarks Sarah K. Emond, MPP, President and CEO, ICER</p>
<p>10:20 AM – 11:00 AM ET</p>	<p>Presentation of the Clinical Evidence Grace Lin, MD, MAS, Medical Director for Health Technology Assessment, ICER Associate Professor of Medicine and Health Policy, University of California, San Francisco</p>
<p>11:00 AM – 11:40 AM ET</p>	<p>Presentation of the Economic Model Woojung Lee, PharmD, PhD, Associate Director of Health Economics and Decision Modeling, ICER</p>
<p>11:40 AM – 11:55 AM ET</p>	<p>Public Comments and Discussion</p>
<p>11:55 AM – 12:45 PM ET</p>	<p>Lunch Break</p>
<p>12:45 PM – 2:00 PM ET</p>	<p>NE CEPAC Vote on Clinical Effectiveness and Value Moderator: Jason H. Wasfy, MD, MPhil Associate Professor, Harvard Medical School Director of Outcomes Research and Cardiologist, Massachusetts General Hospital Heart Center</p>
<p>2:00 PM – 2:15 PM ET</p>	<p>Break</p>
<p>2:15 PM – 3:45 PM ET</p>	<p>Policy Roundtable Moderator: Sarah K. Emond, MPP, President and CEO, ICER</p>
<p>3:45 PM – 4:00 PM ET</p>	<p>Reflections from NE CEPAC</p>
<p>4:00 PM ET</p>	<p>Meeting Adjourned</p>

ICER Staff and External Collaborators	Conflict of Interest
<p>Sarah K. Emond, MPP President & CEO, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>
<p>Shahariar Mohammed Fahim, PhD Research Lead, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>
<p>Chloe Fandetti, BA Operations & Program Coordinator, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>
<p>Anna Geiger, BS Communications Coordinator, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>
<p>Grace Ham, MSc Senior Strategic Partnerships & Events Coordinator, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>
<p>Woojung Lee, PharmD, PhD Associate Director of Health Economics and Decision Modeling</p>	<p>No conflicts to disclose.</p>
<p>Grace Lin, MD, MAS Medical Director for Health Technology Assessment</p>	<p>Financial support provided to Grace Lin from the Institute for Clinical and Economic Review (ICER). Dr. Lin also reports receiving research grant funding from the National Human Genome Research Institute, National Institute on Aging, Mt. Zion Health Fund, GRAIL, Inc., and the California Health Benefits Research Program.</p>
<p>Becca Piltch, MPP Program Manager, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>
<p>Finn Raymond, BS Research Assistant, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>
<p>David Rind, MD, MSc Chief Medical Officer, Institute for Clinical and Economic Review</p>	<p>No conflicts to disclose.</p>

Participating Members of NE CEPAC	Conflict of Interest
<p>Rob Aseltine, PhD Professor and Chair, Division of Behavioral Sciences and Community Health Director, Center for Population Health, UCONN Health</p>	<p>No conflicts to disclose.</p>
<p>Austin Frakt, PhD Vice President and Chief Research Officer, Joint Commission</p>	<p>No conflicts to disclose.</p>
<p>Rebecca Kirch, JD EVP, Policy and Programs for the National Patient Advocate Foundation (NPAF)</p>	<p>No conflicts to disclose.</p>
<p>Stephen Kogut, PhD, MBA, RPh Professor of Pharmacy Practice, University of Rhode Island College of Pharmacy</p>	<p>No conflicts to disclose.</p>
<p>Donald Kreis, JD Consumer Advocate, New Hampshire Office of the Consumer Advocate</p>	<p>No conflicts to disclose.</p>
<p>Julie Kueppers, PhD, FNP Vice President of Clinical Analytics and Advocacy, Alera Group</p>	<p>No conflicts to disclose.</p>
<p>Tara Lavelle, PhD Assistant Professor, Center for the Evaluation of Value and Risk in Health at Tufts Medical Center</p>	<p>No conflicts to disclose.</p>
<p>Kimberly Lenz, PharmD, MBA, FAMCP Chief Pharmacy Officer, MassHealth Office of Clinical Affairs, UMass Chan Medical School</p>	<p>Dr. Kimberly Lenz's employer, MassHealth, currently covers products for Obesity.</p>
<p>Aaron Mitchell, MD, MPH Assistant Attending, Memorial Sloan Kettering Cancer Center</p>	<p>No conflicts to disclose.</p>
<p>Josephine Porter, MPH Chief Strategy Officer, NH Center for Justice and Equity Consultant, Institute for Health Policy and Practice Co-Chair, All-Payer Claims Database Council Board of Director Chair, NH Fiscal Policy Institute and Leadership Team for the NH Food Alliance</p>	<p>No conflicts to disclose.</p>
<p>Jim Rebitzer, PhD Emeritus Peter and Deborah Wexler Professor of Management, Boston University, Questrom School of Business</p>	<p>No conflicts to disclose.</p>
<p>Joseph Ross, MD, MHS Professor of Medicine (General Medicine) and Professor of Public Health (Health Policy and Management), Yale School of Medicine Associate Physician of the Center for Outcomes Research and Evaluation, Yale-New Haven Health System</p>	<p>No conflicts to disclose.</p>

Participating Members of NE CEPAC	Conflict of Interest
Co-Director, National Clinician Scholars Program, Yale University Co-Director, Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI)	
Jason L. Schwartz, PhD Associate Professor, Department of Health Policy and Management, Yale School of Public Health Affiliated with Yale’s Institution for Social and Policy Studies and the Section of the History of Medicine, Yale School of Medicine	No conflicts to disclose.
Jason H. Wasfy, MD, MPhil Associate Professor at Harvard Medical School, Director of Outcomes Research, Massachusetts, General Hospital Cardiology Division Mass General Brigham	No conflicts to disclose.
Stephanie Vail, PharmD, MPH, BCPP, BCPS, FCCP, Professor of Pharmacy Practice, University of New England College of Pharmacy	No conflicts to disclose.

Policy Roundtable Participants	Conflict of Interest
<p>Jason Brett, MD Principal Medical Head, Novo Nordisk Inc.</p>	<p>Dr. Jason Brett is a full-time employee at Novo Nordisk Inc.</p>
<p>Pat Gleason, PharmD, FCCP, FAMCP, BCPS Assistant Vice President, Health Outcomes, Prime Therapeutics, LLC</p>	<p>Dr. Pat Gleason is a full-time employee at Prime Therapeutics.</p>
<p>Alyssa Guest, PharmD Associate Director, Clinical Pharmacy at IPD Analytics</p>	<p>Dr. Alyssa Guest is a full-time employee at IPD Analytics.</p>
<p>Melanie Jay, MD, MS Professor, Departments of Medicine and Population Health, NYU Grossman School of Medicine</p>	<p>No conflicts to disclose.</p>
<p>Joe Nadglowski President/CEO, Obesity Action Coalition</p>	<p>Joe Nadglowski has no personal relationships with industry. The Obesity Action Coalition receives 25% of financial support from health care companies including, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Amgen, Pfizer, AstraZeneca, Boston Scientific, Currax, Genentech, Intuitive, Kailera Therapeutics, Madrigal Pharmaceuticals, Medtronic, Regeneron, Rhythm Pharmaceuticals, Structure Therapeutics, Wave Life Sciences and Zealand Pharma.</p>
<p>Tracy Sims, MA Executive Director, Corporate Affairs, Eli Lilly and Company</p>	<p>Tracy Sims is a full-time employee at Eli Lilly and Company.</p>
<p>Michele Tedder, MSN, RN, BCC Director of Chronic Disease, Black Women's Health Imperative</p>	<p>Michele Tedder is an Obesity Action Coalition board member.</p>
<p>Alexa Triot, MD Clinical Director, Weight Management Programs, and Primary Care Physician, Healthcare Associates at Beth Israel Deaconess Medical Center</p>	<p>Dr. Alexa Triot's spouse works for Verve Therapeutics, a wholly owned subsidiary of Eli Lilly and Company.</p>